{"transactions":[{"id":1946114,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":115410,"kind":"organization","name":"Emerald Health Sciences Inc.","position":1,"cik":"0001728413","reported_name":"Emerald Health Sciences Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants with Credit Facility of Oct 5, 2018 - T3","published_at":"2023-03-17T18:52:02.000Z","date":"2023-02-22","kind":"disposition_to_issuer","acquired":false,"shares":2500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Aggregate exercise price for the warrants was paid through a reduction in the debt Issuer owed to Reporting Person under the Multi Draw Credit Facility."}],"balance_after":0,"derivative":{"exercise_price":0.0386,"exercise_date":"2019-03-29","expiration_date":"2024-03-29","underlying":"Common Stock","underlying_shares":2500000},"source":{"system":"sec-edgar","filing":"0001567619-23-005234","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000156761923005234/doc1.xml","form_type":"4"}},{"id":1946113,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":115410,"kind":"organization","name":"Emerald Health Sciences Inc.","position":1,"cik":"0001728413","reported_name":"Emerald Health Sciences Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants with Credit Facility of Oct 5, 2018 - T2","published_at":"2023-03-17T18:52:02.000Z","date":"2023-02-22","kind":"disposition_to_issuer","acquired":false,"shares":2500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Aggregate exercise price for the warrants was paid through a reduction in the debt Issuer owed to Reporting Person under the Multi Draw Credit Facility."}],"balance_after":0,"derivative":{"exercise_price":0.0386,"exercise_date":"2019-02-01","expiration_date":"2024-02-01","underlying":"Common Stock","underlying_shares":2500000},"source":{"system":"sec-edgar","filing":"0001567619-23-005234","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000156761923005234/doc1.xml","form_type":"4"}},{"id":1946112,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":115410,"kind":"organization","name":"Emerald Health Sciences Inc.","position":1,"cik":"0001728413","reported_name":"Emerald Health Sciences Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants with Credit Facility of Oct 5, 2018","published_at":"2023-03-17T18:52:02.000Z","date":"2023-02-22","kind":"purchase","acquired":false,"shares":2500000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":0.0386,"exercise_date":"2018-11-01","expiration_date":"2023-11-01","underlying":"Common Stock","underlying_shares":2500000},"source":{"system":"sec-edgar","filing":"0001567619-23-005234","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000156761923005234/doc1.xml","form_type":"4"}},{"id":1946111,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":115410,"kind":"organization","name":"Emerald Health Sciences Inc.","position":1,"cik":"0001728413","reported_name":"Emerald Health Sciences Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants","published_at":"2023-03-17T18:52:02.000Z","date":"2023-02-22","kind":"disposition_to_issuer","acquired":false,"shares":9141486,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":0.017,"exercise_date":"2023-11-10","expiration_date":"2024-12-30","underlying":"Common Stock","underlying_shares":9141486},"source":{"system":"sec-edgar","filing":"0001567619-23-005234","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000156761923005234/doc1.xml","form_type":"4"}},{"id":1946110,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":115410,"kind":"organization","name":"Emerald Health Sciences Inc.","position":1,"cik":"0001728413","reported_name":"Emerald Health Sciences Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants","published_at":"2023-03-17T18:52:02.000Z","date":"2022-11-10","kind":"other","acquired":true,"shares":9141486,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Warrants were acquired pursuant to a merger between Issuer and Emerald Health Therapeutics, Inc. (\"Emerald\"), whereby Reporting Person's outstanding warrants to purchase Emerald common stock were exchanged for warrants to purchase Issuer common stock."}],"balance_after":9141486,"derivative":{"exercise_price":0.151,"exercise_date":"2023-11-10","expiration_date":"2024-12-30","underlying":"Common Stock","underlying_shares":9141486},"source":{"system":"sec-edgar","filing":"0001567619-23-005234","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000156761923005234/doc1.xml","form_type":"4"}},{"id":1946109,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":115410,"kind":"organization","name":"Emerald Health Sciences Inc.","position":1,"cik":"0001728413","reported_name":"Emerald Health Sciences Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-03-17T18:52:02.000Z","date":"2023-02-22","kind":"grant","acquired":true,"shares":41379164,"price":0.0386,"value":1597235.7304,"ownership":{"direct":true},"balance_after":169407901,"source":{"system":"sec-edgar","filing":"0001567619-23-005234","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000156761923005234/doc1.xml","form_type":"4"}},{"id":1946108,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":115410,"kind":"organization","name":"Emerald Health Sciences Inc.","position":1,"cik":"0001728413","reported_name":"Emerald Health Sciences Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-03-17T18:52:02.000Z","date":"2023-02-22","kind":"grant","acquired":true,"shares":16641486,"price":0.017,"value":282905.262,"ownership":{"direct":true},"balance_after":128028737,"source":{"system":"sec-edgar","filing":"0001567619-23-005234","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000156761923005234/doc1.xml","form_type":"4"}},{"id":2420883,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":115410,"kind":"organization","name":"Emerald Health Sciences Inc.","position":1,"cik":"0001728413","reported_name":"Emerald Health Sciences Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Multi Draw Credit Facility - T3","published_at":"2022-01-31T18:58:22.000Z","date":"2019-03-29","kind":"grant","acquired":true,"shares":5354861,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transactions were previously reported on various prior Form 4 filings; however, the entries were erroneously reported as non-derivative transactions in Common Stock and the resulting reported total ownership included the misclassified securities.  The entry of these transactions is to correct this error and reflect the actual securities held by the Reporting Person."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Multi Draw Credit Facility tranches have the option to convert into Common Stock upon maturity of the facilities."}],"balance_after":5354861,"derivative":{"exercise_price":0.4,"exercise_date":"2022-10-05","expiration_date":"2022-10-05","underlying":"Common Stock","underlying_shares":5354861},"source":{"system":"sec-edgar","filing":"0001640334-22-000206","document":"form5.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000164033422000206/form5.xml","form_type":"5"}},{"id":2420882,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":115410,"kind":"organization","name":"Emerald Health Sciences Inc.","position":1,"cik":"0001728413","reported_name":"Emerald Health Sciences Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Multi Draw Credit Facility - T2","published_at":"2022-01-31T18:58:22.000Z","date":"2019-02-01","kind":"grant","acquired":true,"shares":38822,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transactions were previously reported on various prior Form 4 filings; however, the entries were erroneously reported as non-derivative transactions in Common Stock and the resulting reported total ownership included the misclassified securities.  The entry of these transactions is to correct this error and reflect the actual securities held by the Reporting Person."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Multi Draw Credit Facility tranches have the option to convert into Common Stock upon maturity of the facilities."}],"balance_after":38822,"derivative":{"exercise_price":0.4,"exercise_date":"2022-10-05","expiration_date":"2022-10-05","underlying":"Common Stock","underlying_shares":38822},"source":{"system":"sec-edgar","filing":"0001640334-22-000206","document":"form5.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000164033422000206/form5.xml","form_type":"5"}},{"id":2420881,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":115410,"kind":"organization","name":"Emerald Health Sciences Inc.","position":1,"cik":"0001728413","reported_name":"Emerald Health Sciences Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants with Credit Facility of Oct 5, 2018","published_at":"2022-01-31T18:58:22.000Z","date":"2019-03-29","kind":"grant","acquired":true,"shares":2500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transactions were previously reported on various prior Form 4 filings; however, the entries were erroneously reported as non-derivative transactions in Common Stock and the resulting reported total ownership included the misclassified securities.  The entry of these transactions is to correct this error and reflect the actual securities held by the Reporting Person."}],"balance_after":2500000,"derivative":{"exercise_price":0.5,"exercise_date":"2019-03-29","expiration_date":"2024-03-29","underlying":"Common Stock","underlying_shares":2500000},"source":{"system":"sec-edgar","filing":"0001640334-22-000206","document":"form5.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000164033422000206/form5.xml","form_type":"5"}},{"id":2420880,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":115410,"kind":"organization","name":"Emerald Health Sciences Inc.","position":1,"cik":"0001728413","reported_name":"Emerald Health Sciences Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants with Credit Facility of Oct 5, 2018","published_at":"2022-01-31T18:58:22.000Z","date":"2019-02-01","kind":"grant","acquired":true,"shares":2500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transactions were previously reported on various prior Form 4 filings; however, the entries were erroneously reported as non-derivative transactions in Common Stock and the resulting reported total ownership included the misclassified securities.  The entry of these transactions is to correct this error and reflect the actual securities held by the Reporting Person."}],"balance_after":2500000,"derivative":{"exercise_price":0.5,"exercise_date":"2019-02-01","expiration_date":"2024-02-01","underlying":"Common Stock","underlying_shares":2500000},"source":{"system":"sec-edgar","filing":"0001640334-22-000206","document":"form5.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000164033422000206/form5.xml","form_type":"5"}},{"id":2420879,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":115410,"kind":"organization","name":"Emerald Health Sciences Inc.","position":1,"cik":"0001728413","reported_name":"Emerald Health Sciences Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants with Credit Facility of Oct 5, 2018","published_at":"2022-01-31T18:58:22.000Z","date":"2018-11-01","kind":"grant","acquired":true,"shares":2500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transactions were previously reported on various prior Form 4 filings; however, the entries were erroneously reported as non-derivative transactions in Common Stock and the resulting reported total ownership included the misclassified securities.  The entry of these transactions is to correct this error and reflect the actual securities held by the Reporting Person."}],"balance_after":2500000,"derivative":{"exercise_price":0.5,"exercise_date":"2018-11-01","expiration_date":"2023-11-01","underlying":"Common Stock","underlying_shares":2500000},"source":{"system":"sec-edgar","filing":"0001640334-22-000206","document":"form5.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000164033422000206/form5.xml","form_type":"5"}},{"id":2420878,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":115410,"kind":"organization","name":"Emerald Health Sciences Inc.","position":1,"cik":"0001728413","reported_name":"Emerald Health Sciences Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-31T18:58:22.000Z","date":"2020-08-07","kind":"sale","acquired":false,"shares":2566666,"price":0.1,"value":256666.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transactions were previously reported on various prior Form 4 filings; however, the entries were erroneously reported as non-derivative transactions in Common Stock and the resulting reported total ownership included the misclassified securities.  The entry of these transactions is to correct this error and reflect the actual securities held by the Reporting Person."}],"balance_after":111387251,"source":{"system":"sec-edgar","filing":"0001640334-22-000206","document":"form5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000164033422000206/form5.xml","form_type":"5"}},{"id":3058332,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":115410,"kind":"organization","name":"Emerald Health Sciences Inc.","position":1,"cik":"0001728413","reported_name":"Emerald Health Sciences Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-08-13T22:35:11.000Z","date":"2020-08-07","kind":"sale","acquired":false,"shares":2566666,"price":0.1,"value":256666.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The original Form 4, filed on August 11, 2020, is being amended by this Form 4 amendment solely to correct an administrative error, which misreported a sale that occurred on August 7, 2020, as a total of 3,000,000 shares sold when in fact 2,566,6660 shares of the Issuer's common stock were sold. As a result of this administrative error, the number of shares beneficially owned by the reporting person following the corrected transaction reflects an addition in the number of shares reported as beneficially owned by the reporting person by 433,334 shares."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The original Form 4, filed on August 11, 2020, is being amended by this Form 4 amendment solely to correct an administrative error, which misreported a sale that occurred on August 7, 2020, as a total of 3,000,000 shares sold when in fact 2,566,6660 shares of the Issuer's common stock were sold. As a result of this administrative error, the number of shares beneficially owned by the reporting person following the corrected transaction reflects an addition in the number of shares reported as beneficially owned by the reporting person by 433,334 shares."}],"balance_after":123923501,"source":{"system":"sec-edgar","filing":"0001640334-20-002100","document":"form4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000164033420002100/form4a.xml","form_type":"4/A","original_submission_date":"2020-08-11"}},{"id":3061518,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":115410,"kind":"organization","name":"Emerald Health Sciences Inc.","position":1,"cik":"0001728413","reported_name":"Emerald Health Sciences Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-08-11T19:15:59.000Z","date":"2020-08-07","kind":"sale","acquired":false,"shares":3000000,"price":0.1,"value":300000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Transfer of shares in a private transaction to directors, employees and consultants."}],"balance_after":123490167,"source":{"system":"sec-edgar","filing":"0001640334-20-002029","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000164033420002029/form4.xml","form_type":"4"}},{"id":3679344,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":115410,"kind":"organization","name":"Emerald Health Sciences Inc.","position":1,"cik":"0001728413","reported_name":"Emerald Health Sciences Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2019-02-01T21:51:08.000Z","date":"2019-02-01","kind":"other","acquired":true,"shares":2500000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The common stock purchase warrant (the \"Warrant\") was issued to the reporting person in connection with the Advance pursuant to the Agreement.  The Warrant is exercisable at the Reporting Person's option, in whole or in part, at any time after issuance. The expiration date is 5 years from the issuance of the Warrant. The Warrant shall continue to be exercisable notwithstanding the repayment in full of the Advance."},{"field":"shares","element":"transactionShares","label":"F3","text":"Represents 50% of the number of shares issuable upon conversion of the Advance."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The common stock purchase warrant (the \"Warrant\") was issued to the reporting person in connection with the Advance pursuant to the Agreement.  The Warrant is exercisable at the Reporting Person's option, in whole or in part, at any time after issuance. The expiration date is 5 years from the issuance of the Warrant. The Warrant shall continue to be exercisable notwithstanding the repayment in full of the Advance."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The common stock purchase warrant (the \"Warrant\") was issued to the reporting person in connection with the Advance pursuant to the Agreement.  The Warrant is exercisable at the Reporting Person's option, in whole or in part, at any time after issuance. The expiration date is 5 years from the issuance of the Warrant. The Warrant shall continue to be exercisable notwithstanding the repayment in full of the Advance."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The common stock purchase warrant (the \"Warrant\") was issued to the reporting person in connection with the Advance pursuant to the Agreement.  The Warrant is exercisable at the Reporting Person's option, in whole or in part, at any time after issuance. The expiration date is 5 years from the issuance of the Warrant. The Warrant shall continue to be exercisable notwithstanding the repayment in full of the Advance."}],"balance_after":2500000,"derivative":{"exercise_price":0.5,"underlying":"Common Stock","underlying_shares":2500000},"source":{"system":"sec-edgar","filing":"0001209191-19-006473","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000120919119006473/doc4.xml","form_type":"4"}},{"id":3679343,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":115410,"kind":"organization","name":"Emerald Health Sciences Inc.","position":1,"cik":"0001728413","reported_name":"Emerald Health Sciences Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"7% Convertible Debt","published_at":"2019-02-01T21:51:08.000Z","date":"2019-02-01","kind":"other","acquired":true,"reported_value":2000000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents an advance of $2,000,000 (the \"Advance\") made by the Reporting Person to the Issuer pursuant to a Multi-Draw Credit Agreement, between the Issuer and the Reporting Person (the \"Agreement\").  The Advance is convertible into shares of the Issuer's common stock, par value $0.001 per share (\"Common Stock\"), at the Reporting Person's option, in whole or in part, at any time after issuance.  The conversion price of $.40 per share of Common Stock will be subject to adjustment for stock dividends, stock splits, dilutive securities issuances and other customary adjustment events.  The maturity date is the earlier of (a) October 5, 2022 and (b) the date on which all amounts under the Agreement shall become due and payable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents an advance of $2,000,000 (the \"Advance\") made by the Reporting Person to the Issuer pursuant to a Multi-Draw Credit Agreement, between the Issuer and the Reporting Person (the \"Agreement\").  The Advance is convertible into shares of the Issuer's common stock, par value $0.001 per share (\"Common Stock\"), at the Reporting Person's option, in whole or in part, at any time after issuance.  The conversion price of $.40 per share of Common Stock will be subject to adjustment for stock dividends, stock splits, dilutive securities issuances and other customary adjustment events.  The maturity date is the earlier of (a) October 5, 2022 and (b) the date on which all amounts under the Agreement shall become due and payable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents an advance of $2,000,000 (the \"Advance\") made by the Reporting Person to the Issuer pursuant to a Multi-Draw Credit Agreement, between the Issuer and the Reporting Person (the \"Agreement\").  The Advance is convertible into shares of the Issuer's common stock, par value $0.001 per share (\"Common Stock\"), at the Reporting Person's option, in whole or in part, at any time after issuance.  The conversion price of $.40 per share of Common Stock will be subject to adjustment for stock dividends, stock splits, dilutive securities issuances and other customary adjustment events.  The maturity date is the earlier of (a) October 5, 2022 and (b) the date on which all amounts under the Agreement shall become due and payable."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents an advance of $2,000,000 (the \"Advance\") made by the Reporting Person to the Issuer pursuant to a Multi-Draw Credit Agreement, between the Issuer and the Reporting Person (the \"Agreement\").  The Advance is convertible into shares of the Issuer's common stock, par value $0.001 per share (\"Common Stock\"), at the Reporting Person's option, in whole or in part, at any time after issuance.  The conversion price of $.40 per share of Common Stock will be subject to adjustment for stock dividends, stock splits, dilutive securities issuances and other customary adjustment events.  The maturity date is the earlier of (a) October 5, 2022 and (b) the date on which all amounts under the Agreement shall become due and payable."}],"derivative":{"exercise_price":0.4,"underlying":"Common Stock","underlying_shares":5000000},"source":{"system":"sec-edgar","filing":"0001209191-19-006473","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000120919119006473/doc4.xml","form_type":"4"}},{"id":3716767,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":115410,"kind":"organization","name":"Emerald Health Sciences Inc.","position":1,"cik":"0001728413","reported_name":"Emerald Health Sciences Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-12-28T23:59:39.000Z","date":"2018-12-27","kind":"other","acquired":true,"shares":37667,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were issued pursuant to the conversion of accrued and unpaid interest on a convertible note, which is no longer outstanding, at the conversion price of $.10 per share."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were issued pursuant to the conversion of accrued and unpaid interest on a convertible note, which is no longer outstanding, at the conversion price of $.10 per share."}],"balance_after":73153917,"source":{"system":"sec-edgar","filing":"0001209191-18-064353","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000120919118064353/doc4.xml","form_type":"4"}},{"id":3777872,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":115410,"kind":"organization","name":"Emerald Health Sciences Inc.","position":1,"cik":"0001728413","reported_name":"Emerald Health Sciences Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2018-11-01T22:45:48.000Z","date":"2018-11-01","kind":"other","acquired":true,"shares":2500000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The common stock purchase warrant (the \"Warrant\") was issued to the reporting person in connection with the Advance pursuant to the Agreement.  The Warrant is exercisable at the Reporting Person's option, in whole or in part, at any time after issuance. The expiration date is 5 years from the issuance of the Warrant. The Warrant shall continue to be exercisable notwithstanding the repayment in full of the Advance."},{"field":"shares","element":"transactionShares","label":"F3","text":"Represents 50% of the number of shares issuable upon conversion of the Advance."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The common stock purchase warrant (the \"Warrant\") was issued to the reporting person in connection with the Advance pursuant to the Agreement.  The Warrant is exercisable at the Reporting Person's option, in whole or in part, at any time after issuance. The expiration date is 5 years from the issuance of the Warrant. The Warrant shall continue to be exercisable notwithstanding the repayment in full of the Advance."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The common stock purchase warrant (the \"Warrant\") was issued to the reporting person in connection with the Advance pursuant to the Agreement.  The Warrant is exercisable at the Reporting Person's option, in whole or in part, at any time after issuance. The expiration date is 5 years from the issuance of the Warrant. The Warrant shall continue to be exercisable notwithstanding the repayment in full of the Advance."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The common stock purchase warrant (the \"Warrant\") was issued to the reporting person in connection with the Advance pursuant to the Agreement.  The Warrant is exercisable at the Reporting Person's option, in whole or in part, at any time after issuance. The expiration date is 5 years from the issuance of the Warrant. The Warrant shall continue to be exercisable notwithstanding the repayment in full of the Advance."}],"balance_after":2500000,"derivative":{"exercise_price":0.5,"underlying":"Common Stock","underlying_shares":2500000},"source":{"system":"sec-edgar","filing":"0001209191-18-056825","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000120919118056825/doc4.xml","form_type":"4"}},{"id":3777871,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":115410,"kind":"organization","name":"Emerald Health Sciences Inc.","position":1,"cik":"0001728413","reported_name":"Emerald Health Sciences Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"7% Convertible Debt","published_at":"2018-11-01T22:45:48.000Z","date":"2018-11-01","kind":"other","acquired":true,"reported_value":2000000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents an advance of $2,000,000 (the \"Advance\") made by the Reporting Person to the Issuer pursuant to a Multi-Draw Credit Agreement, between the Issuer and the Reporting Person (the \"Agreement\").  The Advance is convertible into shares of the Issuer's common stock, par value $0.001 per share (\"Common Stock\"), at the Reporting Person's option, in whole or in part, at any time after issuance.  The conversion price of $.40 per share of Common Stock will be subject to adjustment for stock dividends, stock splits, dilutive securities issuances and other customary adjustment events.  The maturity date is the earlier of (a) October 5, 2022 and (b) the date on which all amounts under the Agreement shall become due and payable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents an advance of $2,000,000 (the \"Advance\") made by the Reporting Person to the Issuer pursuant to a Multi-Draw Credit Agreement, between the Issuer and the Reporting Person (the \"Agreement\").  The Advance is convertible into shares of the Issuer's common stock, par value $0.001 per share (\"Common Stock\"), at the Reporting Person's option, in whole or in part, at any time after issuance.  The conversion price of $.40 per share of Common Stock will be subject to adjustment for stock dividends, stock splits, dilutive securities issuances and other customary adjustment events.  The maturity date is the earlier of (a) October 5, 2022 and (b) the date on which all amounts under the Agreement shall become due and payable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents an advance of $2,000,000 (the \"Advance\") made by the Reporting Person to the Issuer pursuant to a Multi-Draw Credit Agreement, between the Issuer and the Reporting Person (the \"Agreement\").  The Advance is convertible into shares of the Issuer's common stock, par value $0.001 per share (\"Common Stock\"), at the Reporting Person's option, in whole or in part, at any time after issuance.  The conversion price of $.40 per share of Common Stock will be subject to adjustment for stock dividends, stock splits, dilutive securities issuances and other customary adjustment events.  The maturity date is the earlier of (a) October 5, 2022 and (b) the date on which all amounts under the Agreement shall become due and payable."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents an advance of $2,000,000 (the \"Advance\") made by the Reporting Person to the Issuer pursuant to a Multi-Draw Credit Agreement, between the Issuer and the Reporting Person (the \"Agreement\").  The Advance is convertible into shares of the Issuer's common stock, par value $0.001 per share (\"Common Stock\"), at the Reporting Person's option, in whole or in part, at any time after issuance.  The conversion price of $.40 per share of Common Stock will be subject to adjustment for stock dividends, stock splits, dilutive securities issuances and other customary adjustment events.  The maturity date is the earlier of (a) October 5, 2022 and (b) the date on which all amounts under the Agreement shall become due and payable."}],"derivative":{"exercise_price":0.4,"underlying":"Common Stock","underlying_shares":5000000},"source":{"system":"sec-edgar","filing":"0001209191-18-056825","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000120919118056825/doc4.xml","form_type":"4"}},{"id":3971924,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":115410,"kind":"organization","name":"Emerald Health Sciences Inc.","position":1,"cik":"0001728413","reported_name":"Emerald Health Sciences Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series F Convertible Preferred Stock","published_at":"2018-04-04T01:10:41.000Z","date":"2018-03-29","kind":"exercise","acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series F Convertible Preferred Stock is convertible at any time, at the holder's election, and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series F Convertible Preferred Stock is convertible at any time, at the holder's election, and has no expiration date."}],"balance_after":0,"derivative":{"exercise_price":0.1,"underlying":"Common Stock","underlying_shares":20000000},"source":{"system":"sec-edgar","filing":"0001209191-18-023388","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000120919118023388/doc4.xml","form_type":"4"}},{"id":3971923,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":115410,"kind":"organization","name":"Emerald Health Sciences Inc.","position":1,"cik":"0001728413","reported_name":"Emerald Health Sciences Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2018-04-04T01:10:41.000Z","date":"2018-03-29","kind":"exercise","acquired":false,"shares":1233.5,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series B Convertible Preferred Stock is convertible at any time, at the holder's election, and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series B Convertible Preferred Stock is convertible at any time, at the holder's election, and has no expiration date."}],"balance_after":0,"derivative":{"exercise_price":0.1,"underlying":"Common Stock","underlying_shares":12335000},"source":{"system":"sec-edgar","filing":"0001209191-18-023388","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000120919118023388/doc4.xml","form_type":"4"}},{"id":3971922,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":115410,"kind":"organization","name":"Emerald Health Sciences Inc.","position":1,"cik":"0001728413","reported_name":"Emerald Health Sciences Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-04-04T01:10:41.000Z","date":"2018-03-29","kind":"exercise","acquired":true,"shares":20000000,"price":0.1,"value":2000000.0,"ownership":{"direct":true},"balance_after":73116250,"source":{"system":"sec-edgar","filing":"0001209191-18-023388","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000120919118023388/doc4.xml","form_type":"4"}},{"id":3971921,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":115410,"kind":"organization","name":"Emerald Health Sciences Inc.","position":1,"cik":"0001728413","reported_name":"Emerald Health Sciences Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-04-04T01:10:41.000Z","date":"2018-03-29","kind":"exercise","acquired":true,"shares":12335000,"price":0.1,"value":1233500.0,"ownership":{"direct":true},"balance_after":53116250,"source":{"system":"sec-edgar","filing":"0001209191-18-023388","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000120919118023388/doc4.xml","form_type":"4"}},{"id":4019297,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":115410,"kind":"organization","name":"Emerald Health Sciences Inc.","position":1,"cik":"0001728413","reported_name":"Emerald Health Sciences Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Warrant (Right to Buy)","published_at":"2018-03-03T00:46:00.000Z","date":"2018-01-24","kind":"other","acquired":false,"shares":1781250,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":0.001,"exercise_date":"2015-08-20","expiration_date":"2020-08-20","underlying":"Common Stock","underlying_shares":1781250},"source":{"system":"sec-edgar","filing":"0001209191-18-016047","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000120919118016047/doc4.xml","form_type":"4"}},{"id":4019296,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":115410,"kind":"organization","name":"Emerald Health Sciences Inc.","position":1,"cik":"0001728413","reported_name":"Emerald Health Sciences Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-03-03T00:46:00.000Z","date":"2018-01-24","kind":"other","acquired":true,"shares":1781250,"price":0.001,"value":1781.25,"ownership":{"direct":true},"balance_after":40781250,"source":{"system":"sec-edgar","filing":"0001209191-18-016047","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000120919118016047/doc4.xml","form_type":"4"}},{"id":4043571,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":115410,"kind":"organization","name":"Emerald Health Sciences Inc.","position":1,"cik":"0001728413","reported_name":"Emerald Health Sciences Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Warrants (right to buy)","published_at":"2018-02-21T21:32:43.000Z","date":"2018-02-16","kind":"purchase","acquired":true,"shares":20400000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reporting person purchased in a private placement 15,000,000 shares (the \"Shares\") of the Issuer's common stock, par value $0.001 per share (the \"Common Stock\"), and a warrant (the \"Warrant\") to purchase 20,400,000 shares of Common Stock at an exercise price of $0.10 per share. The Shares and the Warrant were purchased as a unit at $.10 per unit."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reporting person purchased in a private placement 15,000,000 shares (the \"Shares\") of the Issuer's common stock, par value $0.001 per share (the \"Common Stock\"), and a warrant (the \"Warrant\") to purchase 20,400,000 shares of Common Stock at an exercise price of $0.10 per share. The Shares and the Warrant were purchased as a unit at $.10 per unit."}],"balance_after":20400000,"derivative":{"exercise_price":0.1,"exercise_date":"2018-02-16","expiration_date":"2023-02-16","underlying":"Common Stock","underlying_shares":20400000},"source":{"system":"sec-edgar","filing":"0001209191-18-011938","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000120919118011938/doc4.xml","form_type":"4"}},{"id":4043570,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":115410,"kind":"organization","name":"Emerald Health Sciences Inc.","position":1,"cik":"0001728413","reported_name":"Emerald Health Sciences Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-02-21T21:32:43.000Z","date":"2018-02-16","kind":"purchase","acquired":true,"shares":15000000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reporting person purchased in a private placement 15,000,000 shares (the \"Shares\") of the Issuer's common stock, par value $0.001 per share (the \"Common Stock\"), and a warrant (the \"Warrant\") to purchase 20,400,000 shares of Common Stock at an exercise price of $0.10 per share. The Shares and the Warrant were purchased as a unit at $.10 per unit."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reporting person purchased in a private placement 15,000,000 shares (the \"Shares\") of the Issuer's common stock, par value $0.001 per share (the \"Common Stock\"), and a warrant (the \"Warrant\") to purchase 20,400,000 shares of Common Stock at an exercise price of $0.10 per share. The Shares and the Warrant were purchased as a unit at $.10 per unit."}],"balance_after":39000000,"source":{"system":"sec-edgar","filing":"0001209191-18-011938","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1516551/000120919118011938/doc4.xml","form_type":"4"}}]}